Answers are grounded in this paper and cite their sources.
The FDA’s approval of apalutamide for use in nonmetastatic castration-resistant prostate cancer (nmCRPC) was based on an improvement in metastasis-free survival. It was the first drug approval for nmCRPC and the first use of this primary end point to support drug approval.
No takes yet. Share an insight, caveat, or question.
Beaver et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: